Tablets - 400 mg + 80 mg
Sulfametoprim contains the active substances sulfamethoxazole and trimethoprim.
Sulfamethoxazole (SMZ) inhibits the bacterial synthesis of dihydrofolic acid, by competing with p-aminobenzoic acid.
Trimethoprim (TMP) inhibits the production of tetrahydrofolic acid, by inhibiting the dihydrofolate reductase enzyme. This combination blocks two consecutive phases of the bacterial biosynthesis of essential nucleic acids and proteins and usually exerts a bactericidal action.
Sulfametoprim tablet is indicated in:
Except pneumonia by Pneumocystis carinii where it is a first-line treatment, toxoplasmosis and nocardiosis, in the other indications such as in the exacerbations of chronic bronchitis, urinary tract infections and in otitis media in children, the use of Sulfametoprim should be carefully considered, only when there is a bacteriological evidence for sensibility to this drug and a strong reason to use it and not a single antibacterial.
Film coated tablets - 400mg
Avacyn contains the active substance moxifloxacin hyrochloride, which belongs to a group of antibiotics called fluoroquinolones. Avacyn works by killing bacteria that cause infections. It is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which moxifloxacin is active.
Avacyn is used for treating the following bacterial infections, when usual antibiotics cannot be used or have not worked:
Avacyn film-coated tablets are not sufficient on their own for treating this kind of infection, therefore, another antibiotic in addition to Avacyn film-coated tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract.
Avacyn film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications:
Avacyn tablets should not be used to initiate therapy for any type of infections of the skin and soft tissue or in severe infections of the lungs.
Tablets - 25 mg
Solution for infusion - 400 mg/250 ml
Solution for injection - (0.1%) 1 mg/1 ml
Oral suspension - (200 mg + 40 mg/5 ml)
